Financial Toxicity of Drugs for the Treatment of Cancer Today

March 2019 Vol 10, No 3

Categories:

Commentary
Lillie D. Shockney, RN, BS, MAS, ONN-CG
Editor-in-Chief, JONS; Program Director, AONN+; University Distinguished Service Professor of Breast Cancer, Administrative Director, The Johns Hopkins Breast Center; Director, Johns Hopkins Cancer Survivorship Programs; Professor of Surgery and Oncology, JHU School of Medicine; Co-Creator, Work Stride-Managing Cancer at Work
shockli@jhmi.edu
Cancer patients have a lot to worry about, beginning with overcoming the shock of the diagnosis, which 1 in 2 men and 1 in 3 women will experience in their lifetime. Despite the staggering incidence, it is rare that a consumer plans ahead for getting diagnosed with some life-threatening cancer and stashes away a ton of money and paid time off from work for when it eventually happens. Most people still believe it won’t happen to them. They also anticipate that their health insurance or Medicare will cover the expenses associated with cancer treatment. The shock after the shock is that third-party payers are not covering cancer treatment 100%. They aren’t covering anything 100%. There are deductibles, copayments, and additional expenses that happen because of the cancer diagnosis and treatment. So how much money might a cancer patient need to fork over personally? Tens of thousands and in some cases hundreds of thousands of dollars. Thus, the new term “financial toxicity” as likely being the worst side effect of treatment. What happens if the patient doesn’t have deep pockets? Well, one of the most common causes of bankruptcy in the United States is bad debt associated with cancer treatment. No doubt you have seen this among your own patients and are working hard to help them get discounted drugs, coverage for copayments by patient advocacy organizations, and other assistance to help them through this financial crisis. The government may have a solution. Yes, you read that correctly—our government. Read on…

The government is working on behalf of patients who have cancer or other chronic illnesses that require drug therapies by taking a closer look at how pricing is determined. How did someone decide how much a specific drug will cost the patient as well as the insurance company, Medicare, and Medicaid? And why does the price not remain consistent over time?

The goal of the government is to curb what equates to billions of dollars in annual rebates that drugmakers give to middlemen in Medicare and instead to pass the rebates on to the consumer. Currently, the middlemen are third parties that manage benefits for Medicare, as well as Medicaid managed care, where states contract with insurers to deliver benefits. Drug manufacturers set list prices but often offer rebates that reduce the amount companies and the federal government actually do pay. These rebates shape the decisions that are made about what drugs are available within some plans as well as their prices. Critics claim this leads to higher prices, without any of these savings being passed on to the patients. If these discounts were redirected to the patients, then obviously drug costs for the patient should drop significantly. There is a catch though. Surprised? The Pharmaceutical Care Management Association, which represents pharmacy benefits managers, said the rule change could increase costs for Medicare beneficiaries in the form of higher premiums and out-of-pocket expenses. But isn’t the intent to reduce the overall monthly out-of-pocket expenses people pay and the cost they have to pay when they seek out care and treatment somewhere?

An estimated $89 billion in rebates was paid to health insurers in 2016, according to a study published by Altarum, a national research firm. This included Medicaid recipients, private health insurance, and Medicare Part D, which is a benefit that is intended to help senior citizens pay for self-administered drugs. And with more and more cancer drugs becoming oral oncolytics, we will probably continue to see this number grow even larger.

Why do drug companies charge so much for a new drug? There is a method to this madness. At any given time, a pharmaceutical company may be working on 15 to 18 research endeavors, each one looking possible to become a new drug therapy for patients with specific types of cancer. Five years into these research efforts taking place in the laboratory, 3 or 4 are deemed not to be as promising as hoped and are discontinued. The research on all the others continues, and a few more years pass, and a couple more are found not to work either. Time from the original idea getting underway in the laboratory to a drug being successfully created that does in fact work for specific types of cancer averages 16 to 18 years. Now tally up all the money spent on the 17 studies that didn’t work, and you have a very large number. Combine that with the 18 years of research spent on the winning drug, and you will see an extraordinarily large amount of overhead that still needs to get paid somehow. So that overhead, if you will, needs to get added into the expenses of the one drug that made it all the way through. There is only a fixed period of time, however, that big dollars are charged for these new and amazing therapies. This is because in the coming years the government will approve the creation of generics and biosimilars, which insurance companies and Medicare will purchase at a much lower price, and the brand-name drug will fall from favor.

There will be a public comment period in the coming months, and this new process could take effect as early as January 2020.

Stay on top of this potential policy change and speak up on behalf of your oncology patients. We need to be their voice. This is a reason why AONN+ has a committee that focuses on regulations, policies, and other government-focused endeavors. We need to cure the nation of financial toxicity associated with cancer care.

Related Articles
The Cancer Advocacy & Patient Education Initiative Because Every Hero Needs a CAPE
Lillie D. Shockney, RN, BS, MAS, ONN-CG
|
August 2019 Vol 10, No 8
Setting Goals and Celebrating the Accomplishments
Lillie D. Shockney, RN, BS, MAS, ONN-CG
|
June 2019 Vol 10, No 6
What Is in the Future for Oncology Patient Navigation?
Lillie D. Shockney, RN, BS, MAS, ONN-CG
|
June 2019 Vol 10, No 6
A reflection on the beginnings of navigation and a vision of its future.
Last modified: March 21, 2019

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code